BTG Reports Positive Results From First Study Investigating BGC20-0166 In Obstructive Sleep Apnoea Patients
Apr 11th 2008Drug InformationSleep / Sleep Disorders
BTG (LSE: BGC), the life sciences company, reports additional details from its positive clinical proof of concept study of BGC20-0166 in subjects with mild to severe obstructive sleep apnea. BGC20-0166 is a novel combination of two marketed serotonin modulating drugs being developed for the treatment of obstructive sleep apnea syndrome (OSA).
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
